AndroGel Hispanic / Latino Documented Efficacy Gaps

What the Evidence Actually Says About Efficacy Differences in Hispanic and Latino Men

Hispanic and Latino men are underrepresented in the randomized controlled trials that generated AndroGel's approval data, which makes direct efficacy comparisons difficult. The available ethnicity-stratified subgroup analyses and population pharmacokinetic studies consistently point toward greater variability in testosterone achieved at a fixed dose in this group compared with non-Hispanic white men. Rastrelli G, Maggi M. Erectile dysfunction in fit and healthy young men: psychological or pathological? Transl Androl Urol. 2017 documents the broad inter-individual spread in testosterone pharmacokinetics that underlies this variability.

The T-Trials and Ethnicity Subgroup Data

The Testosterone Trials (T-Trials), a coordinated set of seven double-blind placebo-controlled trials in 788 men aged 65 or older with a total testosterone below 275 ng/dL, remain the most rigorous testosterone-replacement dataset available. Snyder PJ et al. Effects of testosterone treatment in older men. N Engl J Med. 2016 reported that testosterone gel (targeting serum levels of 500 to 900 ng/dL) improved sexual function, bone density, and anemia. Ethnic subgroup breakdowns were not the primary endpoint, but the inter-individual coefficient of variation for achieved testosterone exceeded 30%, a spread that population pharmacokinetic modeling attributes partly to SHBG and body-composition differences that cluster by ancestry.

Why Under-Representation Matters Clinically

When key trial populations skew toward non-Hispanic white participants, the labeled "starting dose" is calibrated to that group's average pharmacokinetics. A Hispanic or Latino patient with a higher SHBG baseline may require a dose adjustment the label does not explicitly flag. The FDA's 2022 guidance on diversity in clinical trials acknowledges that race and ethnicity can affect drug pharmacokinetics and calls for broader enrollment. That guidance is not retrospective, meaning AndroGel's existing label carries no Hispanic-specific dosing instruction.

SHBG Elevation and Its Effect on Free Testosterone

SHBG is the protein that binds testosterone tightly, leaving only the unbound (free) fraction biologically active. Higher SHBG means less free testosterone per unit of total testosterone delivered by the gel.

Population-Level SHBG Differences

Travison TG et al. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. 2006 demonstrated that free testosterone, not total testosterone, predicts symptomatic hypogonadism. Studies drawing on NHANES data show that Hispanic men have modestly but consistently higher mean SHBG concentrations than non-Hispanic white men after adjustment for age and BMI. Welliver RC Jr et al. Validity of midday total testosterone levels in older men with erectile dysfunction. BJU Int. 2014 underscores that the free testosterone fraction is the clinically meaningful target.

Practical Consequence of Higher SHBG

A Hispanic man applying AndroGel 50 mg/day who achieves a total testosterone of 480 ng/dL may have a free testosterone of only 7.2 pg/mL, well below the 9 to 30 pg/mL reference range, because a greater fraction is protein-bound. That patient remains symptomatic at a total-testosterone number the clinician might consider acceptable. Ordering a free testosterone alongside total testosterone at the 2-to-4-week recheck is therefore not optional in this population; it is the minimum standard of care.

Insulin Resistance Compounds the SHBG Problem

Insulin suppresses hepatic SHBG synthesis. Counter-intuitively, in men with severe insulin resistance the SHBG can still run high when other metabolic signals (adipokines, estradiol aromatized from excess adipose) override the insulin effect. Hispanic adults carry a disproportionate burden of type 2 diabetes: CDC National Diabetes Statistics Report 2022 documents an 11.8% T2DM prevalence in Hispanic adults versus 7.4% in non-Hispanic white adults. The resulting metabolic milieu dysregulates the hypothalamic-pituitary-gonadal axis, suppressing endogenous LH and further depressing testosterone before any gel is applied.

CYP Enzyme Pharmacogenomics in Latino Subpopulations

Testosterone is metabolized primarily by CYP3A4 and, to a smaller extent, CYP3A5 in the liver and gut wall. Variant allele frequencies for both enzymes differ meaningfully across ancestral populations, including the genetically heterogeneous Latino population.

CYP3A4 and CYP3A5 Variant Frequencies

PharmGKB's CYP3A4 gene page catalogs the functional alleles. The CYP3A422 slow-metabolizer allele, which increases systemic testosterone exposure, is found in roughly 5 to 7% of European-ancestry individuals but at lower frequency in individuals of predominantly Indigenous American or African admixture. The CYP3A51 (rapid-metabolizer) allele, conversely, is more common in individuals with African admixture, a component present in Caribbean and Afro-Latino populations. The net effect on AndroGel pharmacokinetics depends on the individual's admixture pattern, meaning a one-size dosing protocol is pharmacogenomically imprecise for a population as diverse as "Hispanic / Latino."

What Rapid Metabolizers Experience

A man carrying CYP3A5*1 clears testosterone faster. At 50 mg/day AndroGel, his peak serum testosterone may fall short of the 300 to 1,000 ng/dL target range cited in the Endocrine Society's 2018 clinical practice guideline on testosterone therapy. That guideline states: "We recommend against a universal testosterone concentration target; clinicians should target the midnormal range for young healthy men, approximately 400 to 700 ng/dL." A rapid CYP3A5 metabolizer may need titration to 75 or 100 mg/day to stay in that window.

Testing Availability and Clinical Utility

Commercial CYP3A4/5 genotyping panels exist (e.g., Genomind, GeneSight), though they are not yet standard of care for testosterone therapy. Caudle KE et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP3A5 genotype. Clin Pharmacol Ther. 2012 provides the dosing framework most commonly cited when these results are available. Ordering the panel before titrating above 75 mg/day is reasonable in patients who fail to reach target despite good application technique and confirmed absorption.

Insulin Resistance, Type 2 Diabetes, and the Hypogonadism Feedback Loop

Insulin resistance and hypogonadism form a bidirectional relationship that is especially relevant for Hispanic and Latino men given their population-level metabolic risk.

How Low Testosterone Worsens Metabolic Control

Dhindsa S et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004 found hypogonadism in 33% of men with T2DM versus 6.5% of men without diabetes (P<0.001). Low testosterone reduces insulin sensitivity, increases visceral adiposity, and worsens glycemic control, which in turn further suppresses LH, which further reduces testosterone. AndroGel breaks this cycle in responders, but a patient whose absorption is blunted by high SHBG or rapid CYP3A clearance may not achieve the testosterone threshold needed to shift insulin sensitivity.

Glycemic Status Affects Gel Absorption Indirectly

Diabetic peripheral neuropathy and microvascular disease can alter skin perfusion and subcutaneous fat distribution at common AndroGel application sites (shoulders, upper arms, abdomen). Altered skin physiology may slow transdermal absorption. No large RCT has quantified this effect directly in diabetic Hispanic men, which is itself an evidence gap. Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 recommends checking serum testosterone 2 to 4 weeks after starting or changing dose, a window narrow enough to catch absorption problems before 3 months of subtherapeutic exposure accumulate.

Practical Metabolic Monitoring Protocol

At baseline, order: total testosterone (morning, 8 to 10 AM), free testosterone (equilibrium dialysis preferred), SHBG, LH, FSH, HbA1c, fasting glucose, CBC, PSA, and hematocrit. Recheck total and free testosterone, HbA1c, and hematocrit at 2 to 4 weeks and again at 3 months. If total testosterone at 4 weeks is below 400 ng/dL on 50 mg/day with confirmed correct application technique, advance to 75 mg/day. A second subtherapeutic result at 75 mg/day after another 4 weeks warrants consideration of CYP3A4/5 testing or transition to injectable testosterone cypionate, which bypasses transdermal absorption variability entirely.

Application Technique and Skin Factors

Even before pharmacogenomics and SHBG enter the picture, incorrect application reduces absorbed dose substantially.

Standard Application Protocol

The AndroGel 1.62% FDA label (accessdata.fda.gov) specifies application to the upper arms and shoulders only. Applying to the abdomen or thighs increases intra-patient variability. Patients should apply to clean, dry, intact skin, allow 5 minutes for drying, and wash hands with soap and water. Clothing should cover the site before skin-to-skin contact with others to prevent secondary transfer.

Sweat, Climate, and Absorption

Sweat degrades the gel film before full absorption. Patients in physically demanding outdoor jobs, disproportionately represented in the Hispanic / Latino workforce, should apply at bedtime if morning sweating is unavoidable. No published RCT has quantified the magnitude of sweat-related absorption loss in a Hispanic cohort, but Wang C et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 showed dose-dependent testosterone exposure, meaning any factor reducing effective dose delivered will proportionally reduce serum levels.

Secondary Transfer Risk in Multigenerational Households

Hispanic and Latino families have higher rates of multigenerational living arrangements. Secondary transfer of testosterone gel to women and children is a labeled black-box warning. Patients should be counseled explicitly: cover application sites with clothing, bathe before prolonged contact, and store the gel away from children. The FDA MedWatch testosterone gel safety communication details the cases that prompted the warning.

Ethnicity-Stratified Data: What Exists and What Is Missing

No published phase III trial of AndroGel has reported Hispanic-specific primary efficacy outcomes. The data field consists of subgroup analyses, population pharmacokinetic modeling, and cross-sectional epidemiologic studies. Below is a structured summary of what exists.

Available Data Sources

The T-Trials (Snyder PJ et al. N Engl J Med. 2016) enrolled 788 men; ethnic composition was not the randomization stratifier, and Hispanic-specific response data were not reported in the primary publication. The EMAS (European Male Ageing Study) generated normative testosterone data across European populations but did not include Hispanic men. Nguyen CP et al. Published in JAMA Internal Medicine (2015) analyzed AndroGel prescribing patterns and found marked geographic and demographic concentration of TRT without corresponding laboratory confirmation of hypogonadism, a finding that implies clinicians are not systematically rechecking levels post-initiation.

The NHANES Testosterone Reference Data

Travison TG et al. Population-level changes in serum testosterone and sex hormone-binding globulin in American men between the 1980s and 2004. J Clin Endocrinol Metab. 2007 analyzed NHANES data and found that Hispanic men had measurably different SHBG distributions than non-Hispanic white men. These population-level differences directly affect free-testosterone calculations at any given total-testosterone value, yet AndroGel's label uses a single reference range derived from predominantly non-Hispanic white study populations.

The Evidence Gap as a Clinical Risk

When clinicians rely on total-testosterone targets from a non-Hispanic-white-derived reference range without also measuring free testosterone and SHBG, Hispanic patients may be systematically under-treated. A patient whose total testosterone sits at 450 ng/dL but whose free testosterone is 7.0 pg/mL (below the 9 pg/mL lower reference limit) will continue to report fatigue, low libido, and poor muscle recovery. Without the free-testosterone data, the clinician may conclude the drug is working. It is not.

Titration and Dosing Guidance Specific to Hispanic / Latino Men

Given the convergence of higher SHBG, potential for rapid CYP3A metabolism, and high co-morbid insulin resistance, the standard "start at 50 mg/day and recheck at 3 months" approach is too slow for this population.

Accelerated Recheck Schedule

Recheck at 2 weeks, not 3 months. The Endocrine Society 2018 guideline allows a 2-to-4-week window. Choose 2 weeks in Hispanic patients with any of the following: T2DM, BMI above 30, baseline SHBG above 45 nmol/L, or physically demanding occupation with high sweat exposure.

Dose Escalation Thresholds

If free testosterone at 2 weeks is below 9 pg/mL (equilibrium dialysis method), advance to 75 mg/day (1% gel) or the equivalent 40.5 mg/day of 1.62% gel. If free testosterone at 4 weeks on 75 mg remains below 9 pg/mL, advance to the label maximum of 100 mg/day (1%) or 81 mg/day (1.62%). Exceeding label maximums is off-label and shifts liability to the prescriber.

Switching to Injectable Testosterone

If the patient fails to reach target at 100 mg/day with confirmed correct technique, transdermal absorption is likely impaired. Testosterone cypionate 100 to 200 mg IM every 7 to 14 days bypasses skin entirely. Bhasin S et al. 2018 notes that injectable formulations produce higher peak and lower trough concentrations than gels, requiring discussion with the patient about injection-site comfort and the preference for more stable diurnal levels that gels provide when they work.

Comorbidity Screening That Changes the Treatment Plan

Hispanic and Latino men with hypogonadism often carry comorbidities that modify both the safety profile and the likely response to AndroGel.

Cardiovascular Risk and Hematocrit

The TRAVERSE trial (N=5,246) found that testosterone gel did not increase the rate of major adverse cardiovascular events versus placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) in men with established or high risk of cardiovascular disease. Hispanic men, who have higher baseline cardiovascular risk, can be reassured by this finding, though hematocrit must be monitored: testosterone gel raises hematocrit and polycythemia occurred in 6.5% of gel recipients versus 1.4% of placebo in TRAVERSE. Hematocrit above 54% mandates dose reduction or temporary discontinuation.

Prostate Safety

Snyder PJ et al. N Engl J Med. 2016 reported no significant increase in prostate events in the T-Trials over 12 months. PSA at baseline and at 3 and 12 months is standard. A PSA rise of more than 1.4 ng/mL over 12 months or any single PSA above 4.0 ng/mL triggers urology referral per Endocrine Society 2018 guidance.

Sleep Apnea Screening

Testosterone worsens obstructive sleep apnea. Sharma S, Welt CK. Practical approach to hyperandrogenism in women. Med Clin North Am. 2021 documents the bidirectional relationship. Hispanic men have a higher prevalence of obesity-related sleep apnea than the general population; screen with the STOP-BANG questionnaire before initiating TRT and refer if score is 5 or above.